国防部批准Symvess上市，Humacyte股价上涨

2025-07-08 21:53

Shares of Humacyte (NYSE:HUM) traded ~16% higher on Tuesday after the U.S. Defense Logistics Agency issued an Electronic Catalog (ECAT) listing approval for its vascular repair product Symvess, making it more readily accessible for patients.
ECAT is an internet solution through which commercial catalogs of multiple manufacturers and distributors are available at discounted prices for the DoD and other federal agencies.
The decision is expected to make Symvess readily accessible for patients under the care of DOD and U.S. Department of Veterans Affairs facilities.
“We are pleased that Symvess is now listed in the ECAT system, making the product more readily available to healthcare professionals treating military personnel and their families,” Humacyte (NYSE:HUM) CEO Laura Niklason remarked.
In December, the FDA approved the bioengineered product for certain adults with arterial injury in the extremities.

More on Humana